Article Information
History
- October 29, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Helen J. Mayfield1,*,
- Colleen L. Lau1,
- Jane E. Sinclair2,
- Samuel J. Brown2,
- Andrew Baird3,
- John Litt4,5,
- Aapeli Vuorinen6,
- Kirsty R. Short2,
- Michael Waller1 and
- Kerrie Mengersen7
- 1School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
- 2School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, Queensland, Australia
- 3St Kilda Medical Group, St Kilda, Melbourne, Victoria, Australia
- 4Discipline of General Practice, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
- 5Scientific Advisory Committee, Immunisation Coalition, Melbourne, Victoria, Australia
- 6Data Science Institute, Columbia University, New York, New York, U.S.A.
- 7School of Mathematical Sciences, Faculty of Science, Queensland University of Technology, Brisbane, Queensland, Australia
- ↵*Corresponding author:
Dr Helen Mayfield, School of Public Health, Faculty of Medicine, The University of Queensland, 288 Herston Rd, Herston, Brisbane, Queensland 4006, Australia. Email: h.mayfield{at}uq.edu.au
Posted October 29, 2021.
Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine
